Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00222521 | Insulin Glargine Vs Standard Insulin Therapy | PHASE3 | COMPLETED | 20 | — | — | Apr 1, 2003 | Aug 1, 2005 | Sep 22, 2005 | 1 | United States |
| Name | Type | Description |
|---|---|---|
| Glargine insulin | DRUG | - |
1. Inclusion Criteria 1. CFRD with fasting hyperglycemia (fasting plasma glucose ≥126 mg/dl) 1. . The diagnosis must be made at a time when the patient is in his/her basal state of health with no evidence of acute exacerbation in the preceding two months. a). Acute exacerbation ...